The company said in a securities filing it expects to enter into and announce final agreements with the Securities and Exchange Commission and the Justice Department by the end of the year. The alleged misconduct has to do with “potentially improper payments made by certain Pfizer and Wyeth subsidiaries” connected to sales outside the U.S., the filing said.
via blogs.wsj.com
No comments:
Post a Comment